Coegin Pharma's strategy is to build a risk-balanced pipeline through the acquisition of product candidates in preclinical and early development stages. We actively seek strategic collaborations with researchers and companies to enable and accelerate the development of our projects.
We are flexible regarding the structure of the agreement and can include licenses, partnerships, joint ventures, option agreements and others. We recognize and support the interest of many entrepreneurs and universities in forming new companies around their inventions.
We are open to out-licensing, possible strategic partnerships for our breakthrough drug candidates and commercial players for the distribution and marketing of our innovative dermacosmetic products.
If you would like to know more about the specific assets and portfolio companies, please visit:
Please contact Tore Duvold, CEO of Coegin Pharma AB via [email protected].